MODAFOCUS 200

What is MODAFOCUS 200?

MODAFOCUS 200 is a tablet medication based on modafinil, belonging to the pharmacological group of psychostimulants and wakefulness-promoting agents. The drug is available in oral tablet form with an active ingredient dosage of 200 mg, providing a pronounced therapeutic effect over an extended period. The manufacturer of MODAFOCUS 200 is the pharmaceutical company Kachhela, which specializes in producing high-quality generics and innovative nootropic agents. The pharmacological action of the drug is aimed at activating certain areas of the brain responsible for the sleep-wake cycle, which allows it to effectively combat excessive daytime sleepiness. MODAFOCUS 200 is not a classic amphetamine stimulant, so it carries a significantly lower risk of dependence and less pronounced cardiovascular side effects.

The mechanism of action of MODAFOCUS 200 is based on a selective effect on the neurotransmitter systems of the brain, particularly the metabolism of dopamine, norepinephrine, and histamine. The drug blocks dopamine reuptake, increasing its concentration in the synaptic cleft, which leads to enhanced cognitive functions and a feeling of alertness. Unlike traditional psychostimulants, MODAFOCUS 200 does not cause euphoria or a sharp rise in blood pressure, making its use safer in clinical practice. The therapeutic effect develops gradually over 1–2 hours after ingestion and lasts up to 12–15 hours, allowing for once-daily dosing. Thanks to this action profile, MODAFOCUS 200 is widely used in patients requiring sustained concentration and high mental performance.

MODAFOCUS 200 is supplied in blister packs, ensuring convenient dosing and protection from moisture and light. Each tablet contains a precisely calibrated amount of the active substance, guaranteeing the stability of the therapeutic effect from dose to dose. The drug has undergone the necessary bioequivalence studies confirming its compliance with original modafinil in key pharmacokinetic parameters. The manufacturer, Kachhela, adheres to international GMP quality standards at all stages of production, ensuring the purity and safety of every batch. MODAFOCUS 200 is available by prescription only, as it requires prior medical examination and the exclusion of contraindications.

What is MODAFOCUS 200 prescribed for?

MODAFOCUS 200 is prescribed primarily for the treatment of narcolepsy — a chronic neurological disorder characterized by uncontrollable daytime sleep attacks. Patients with narcolepsy experience sudden loss of muscle tone, hallucinations upon falling asleep and waking up, as well as severe daytime sleepiness that significantly reduces quality of life. MODAFOCUS 200 helps stabilize the sleep-wake cycle, reducing the frequency of sudden falling asleep episodes and improving overall daytime activity levels. Clinical studies demonstrate that regular intake of the drug enables patients to return to normal professional and social activities without the constant fear of unexpected sleep.

The second important indication for the use of MODAFOCUS 200 is obstructive sleep apnea syndrome, in which the patient suffers from repeated breathing pauses during sleep. Even after successful treatment of the underlying condition using CPAP machines, many patients continue to experience residual daytime sleepiness requiring pharmacological correction. MODAFOCUS 200 effectively eliminates this residual sleepiness, improving focus and reaction speed during daytime hours. The drug does not replace primary apnea therapy, but significantly enhances its effectiveness and the patient's quality of life.

In modern medical practice, MODAFOCUS 200 is also used for shift work sleep disorder, when a person works night shifts or a rotating schedule. Disruption of circadian rhythms leads to chronic sleep deprivation, decreased cognitive function, and an increased risk of errors in the workplace. Taking MODAFOCUS 200 helps adapt the body to an unconventional schedule, maintaining an optimal level of alertness during periods when the person must be active. The drug is also used in the comprehensive therapy of chronic fatigue syndrome and cognitive impairment associated with depressive states, although such use requires special caution and medical supervision.

Composition and active components of MODAFOCUS 200

The main active substance of MODAFOCUS 200 is modafinil at a dosage of 200 mg per tablet. Modafinil is a synthetic compound from the benzhydrylsulfinylacetamide group that exerts a pronounced wakefulness-promoting effect without significant impact on the peripheral nervous system. The mechanism of action of modafinil involves blocking the dopamine transporter, leading to an increase in extracellular dopamine concentration in the prefrontal cortex and hypothalamus. Additionally, modafinil affects histamine, norepinephrine, and serotonin receptors, creating a complex effect of increased alertness and cognitive enhancement. Unlike amphetamines, modafinil does not cause a massive release of monoamines, explaining its lower abuse potential.

The excipients of MODAFOCUS 200 include lactose monohydrate, microcrystalline cellulose, corn starch, povidone, magnesium stearate, and talc. Lactose monohydrate acts as a filler, providing the necessary tablet mass and structural stability. Microcrystalline cellulose promotes an even distribution of the active substance within the tablet and improves its disintegration in the gastrointestinal tract. Corn starch acts as a disintegrant, accelerating the release of modafinil after ingestion. Magnesium stearate and talc are used as lubricants to prevent the tablet mass from sticking to the tableting equipment.

The pharmacokinetic profile of MODAFOCUS 200 is characterized by rapid absorption in the gastrointestinal tract, reaching peak plasma concentration within 2–3 hours after administration. The bioavailability of the drug is approximately 80%, and plasma protein binding is around 60%. Modafinil is metabolized primarily in the liver by the CYP3A4 cytochrome system, as well as via hydrolysis and oxidation to form inactive metabolites. The elimination half-life is 12–15 hours, allowing a stable concentration of the drug to be maintained throughout the day with a single daily dose. Excretion of metabolites occurs mainly via the kidneys, so patients with impaired renal function may require dose adjustments.

Dosage of MODAFOCUS 200

The standard recommended dose of MODAFOCUS 200 for adult patients is 200 mg once daily, preferably in the morning or 1 hour before the start of a work shift. For patients with narcolepsy and obstructive sleep apnea syndrome, the drug is taken in the morning to provide maximum effect during daytime activity. For shift work sleep disorder, MODAFOCUS 200 is taken 1 hour before starting the night shift, maintaining the necessary level of alertness throughout the work night. In some cases, a physician may recommend dividing the daily dose into two administrations, but such a decision is made individually based on patient characteristics.

The maximum daily dose of MODAFOCUS 200 should not exceed 400 mg, although the standard dose of 200 mg is sufficient for most patients. Elderly patients and individuals with impaired hepatic function are recommended to initiate therapy with a dose of 100 mg daily, followed by titration under medical supervision. The duration of the treatment course is determined individually depending on the diagnosis and response to therapy. In narcolepsy and sleep apnea, the drug may be prescribed for long-term use, whereas for shift work sleep disorder, use is restricted to night shift periods. It is important not to exceed the prescribed dose or extend the course of treatment without consulting a doctor.

Dose adjustment of MODAFOCUS 200 may be necessary when co-administered with other medications affecting hepatic enzymes. In particular, CYP3A4 cytochrome inducers may decrease modafinil blood concentration, whereas inhibitors of this enzyme may increase the risk of side effects. Patients with severe renal impairment are advised to reduce the dose or increase the dosing interval. Abrupt cessation of MODAFOCUS 200 does not typically cause a pronounced withdrawal syndrome, but a gradual dose reduction is a more physiological approach. Any dosage changes must be agreed with the prescribing physician.

How to take MODAFOCUS 200 correctly?

MODAFOCUS 200 is taken orally with a sufficient amount of water, regardless of food intake. However, it should be noted that taking the drug with fatty food may delay its absorption and postpone the onset of the therapeutic effect by 1–2 hours. To achieve maximum efficacy, it is recommended to take the tablet at the same time every day, helping to maintain a stable drug concentration in the body. The tablet should be swallowed whole without chewing or crushing, as breaking the tablet's integrity may alter the rate of active substance release. Taking MODAFOCUS 200 in the afternoon may cause difficulty falling asleep, so the drug is recommended to be taken no later than 12:00–13:00 under a standard daily schedule.

If a patient misses a dose of MODAFOCUS 200, it should be taken as soon as possible if there are more than 6–8 hours remaining until the next scheduled dose. If the time for the next dose is approaching, the missed dose should be skipped, and the regular dosing schedule resumed. It is strictly forbidden to double the dose to make up for a missed one, as this may lead to an overdose and the development of severe side effects. Shift workers should agree with their doctor on the optimal time for taking the drug, taking into account the alternation of day and night shifts. It is important to remember that MODAFOCUS 200 does not replace full sleep, so even during therapy, it is necessary to provide the body with adequate rest.

While taking MODAFOCUS 200, it is recommended to avoid consuming large amounts of caffeinated beverages, as this may potentiate the stimulating effect and cause tachycardia, tremors, or increased anxiety. Patients should regularly monitor blood pressure and heart rate, especially at the start of therapy. If severe headache, nausea, or sleep disturbances occur, a doctor should be consulted for dose adjustment or treatment scheme revision. MODAFOCUS 200 may reduce the effectiveness of hormonal contraceptives, so women of reproductive age are advised to use additional contraceptive methods during therapy and for one month after its completion. The medication should be stored out of reach of children at a temperature not exceeding 25°C.

Side effects of MODAFOCUS 200

The most common side effect of MODAFOCUS 200 is headache, occurring in approximately 10–15% of patients, particularly at the beginning of therapy. Headaches are usually mild to moderate, diminish within the first days of intake, and respond well to treatment with common analgesics. Other common adverse reactions include nervousness, insomnia, loss of appetite, dry mouth, and feelings of anxiety. These symptoms most frequently arise when the recommended dose is exceeded or when the drug is taken in the afternoon. In most cases, side effects are transient and resolve spontaneously after the body adapts to the drug.

Uncommon side reactions of MODAFOCUS 200 include tachycardia, elevated blood pressure, chest pain, dizziness, and paresthesias. Gastrointestinal disturbances may include nausea, diarrhea, dyspepsia, and abdominal discomfort. Skin reactions such as rash, pruritus, or urticaria have been reported in some patients and require immediate medical consultation. Psychiatric side effects may include depression, agitation, aggression, hallucinations, and manic episodes, particularly in patients with a history of psychiatric disorders. If any unusual symptoms appear, administration of the drug should be discontinued and medical help sought.

Rare but severe side effects of MODAFOCUS 200 include severe allergic reactions, including angioedema and anaphylaxis, as well as Stevens-Johnson syndrome and toxic epidermal necrolysis. These conditions require immediate discontinuation of the drug and emergency medical care. Patients should seek immediate medical attention upon experiencing fever, rash, facial or tongue swelling, or difficulty breathing or swallowing. It is important to remember that individual body responses to the drug may vary; therefore, even in the absence of described side effects, one must carefully monitor their well-being. Regular medical supervision during MODAFOCUS 200 therapy allows for the timely detection and management of any adverse reactions.

Contraindications of MODAFOCUS 200

MODAFOCUS 200 has a number of absolute contraindications in the presence of which the drug is strictly prohibited. These include hypersensitivity to modafinil or any auxiliary component of the formulation, as well as a history of severe allergic reactions to other psychostimulants. The drug is not prescribed to patients with uncontrolled arterial hypertension, severe cardiac arrhythmias, hypertrophic cardiomyopathy, and other serious cardiovascular diseases. MODAFOCUS 200 is contraindicated in psychotic disorders, severe depression with psychotic symptoms, and bipolar affective disorder, as it may trigger an exacerbation of psychiatric symptoms. The drug is also not used in patients with severe liver cirrhosis and marked hepatic impairment.

Relative contraindications for MODAFOCUS 200 include conditions where the drug may be prescribed only with special caution and under close medical supervision. This applies to patients with moderate arterial hypertension, ischemic heart disease, a history of cardiac arrhythmias, and recent myocardial infarction. Caution is required when prescribing the drug to patients with epilepsy, as modafinil may lower the seizure threshold. Patients with renal impairment require dose adjustment and regular monitoring of renal function. Individuals with a history of psychiatric disorders, including depression and anxiety disorders, are prescribed MODAFOCUS 200 only after a careful benefit-risk assessment.

The use of MODAFOCUS 200 during pregnancy is not recommended, as animal studies have shown potential risks to fetal development. Women of childbearing potential should use reliable methods of contraception during therapy and for at least one month after its completion. The drug is not prescribed to children and adolescents under 18 years of age due to the lack of sufficient safety and efficacy data in this age group. In elderly patients, MODAFOCUS 200 is prescribed with caution, starting with minimal doses, as hepatic and renal function impairments are observed more frequently in this group. Before starting MODAFOCUS 200 therapy, a consultation with a physician is mandatory to rule out all possible contraindications and assess overall health status.

Interaction of MODAFOCUS 200 with other drugs and alcohol

MODAFOCUS 200 can interact with many medications, so before initiating therapy, it is necessary to inform your doctor about all drugs taken on a regular basis. Modafinil is an inducer of cytochrome P450 enzymes, notably CYP3A4, CYP2C19, and CYP1A2, which leads to accelerated metabolism of many drugs and a decrease in their efficacy. Particularly important is the interaction with hormonal contraceptives, the effectiveness of which is significantly reduced when co-administered with modafinil. The drug also lowers blood concentrations of cyclosporine, warfarin, certain antidepressants, anticonvulsants, and antiviral agents, which may require dose adjustment. Concomitant use of MODAFOCUS 200 with MAO inhibitors, tricyclic antidepressants, and selective serotonin reuptake inhibitors requires extreme caution due to the risk of serotonin syndrome.

Alcohol consumption during MODAFOCUS 200 therapy is not recommended, as ethanol can intensify the drug's side effects on the central nervous system. Alcohol can mask the effects of modafinil, creating a false sense of sobriety and increasing the risk of hazardous behavior. Furthermore, combining alcohol with MODAFOCUS 200 increases the strain on the liver and may lead to unpredictable physiological reactions. The drug may affect reaction speed and the ability to drive vehicles; therefore, at the beginning of therapy, one should refrain from driving until their individual reaction to the medication is established. Patients who operate machinery or perform potentially dangerous work should exercise extreme caution while taking MODAFOCUS 200.

Where to buy MODAFOCUS 200 in Ukraine

MODAFOCUS 200 is available in Ukraine through a network of licensed pharmacies and specialized online platforms that sell pharmaceuticals in compliance with current legislation. The medication is dispensed by prescription only; therefore, a valid medical prescription is required to purchase it. When buying MODAFOCUS 200, it is important to pay attention to packaging integrity, expiration date, and the presence of protective elements confirming product authenticity. It is recommended to purchase the drug only from verified suppliers who can provide certificates of quality and confirmation of origin from the manufacturer, Kachhela.

Storage conditions for MODAFOCUS 200 require keeping the drug in its original packaging at a temperature not exceeding 25°C in a place protected from moisture and direct sunlight. The shelf life of the preparation is 36 months from the date of manufacture, after which use is strictly prohibited. Many online pharmacies offer convenient delivery of MODAFOCUS 200 across Ukraine, which is particularly relevant for patients with limited mobility or those living in remote locations. Before ordering the drug online, ensure that the platform holds a valid retail license for pharmaceutical sales. Self-medication with MODAFOCUS 200 is unacceptable; therefore, prior to purchase and use, consultation with a qualified doctor is mandatory to determine the appropriateness of therapy and correct dosing.